KeithDanielsKaufmanMD

PubMed

• 3 citations
  Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism.
  R Ravi Shankar, Suneri Shah, Hee-Koung Joeng, Geraldine Mendizabal, Julia R DiBello, Yanfen Guan, Barbara J Stegmann, Eberhard Nieschlag, Hermann M Behre, Ronald S Swe...> ;The Journal of Clinical Endocrinology and Metabolism. 2022 Jun 16
• 12 citations
  Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin
  Muhammad Yazid Jalaludin, Asma Deeb, Philip Zeitler, Raymundo Garcia, Ron S. Newfield, Yulia Samoilova, Carmen A. Rosario, Naim Shehadeh, Chandan Saha, Yilong Zhang, M...> ;Pediatric Diabetes. 2021 Nov 14
• 12 citations
  A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes
  R. Ravi Shankar, Philip Zeitler, Asma Deeb, Muhammad Yazid Jalaludin, Raymundo Garcia, Ron S. Newfield, Yulia Samoilova, Carmen A. Rosario, Naim Shehadeh, Chandan Saha...> ;Pediatric Diabetes. 2021 Nov 14
• 18 citations
  Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precisio...
  Abhinav Sharma, Yinggan Zheng, Justin A. Ezekowitz, Cynthia M. Westerhout, Jacob A. Udell, Shaun G. Goodman, Paul W. Armstrong, John B. Buse, Jennifer B. Green, Robert...> ;Diabetes Care. 2021 Oct 29
• 4 citations
  Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
  Kohei Kaku, Takashi Kadowaki, Yutaka Seino, Taro Okamoto, Masayoshi Shirakawa, Asako Sato, Edward A. O'Neill, Samuel S. Engel, Keith D. Kaufman> ;Diabetes, Obesity & Metabolism. 2021 Sep 1
• A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on i...
  Yutaka Seino, Kohei Kaku, Takashi Kadowaki, Taro Okamoto, Asako Sato, Masayoshi Shirakawa, Edward A. O'Neill, Samuel S. Engel, Keith D. Kaufman> ;Diabetes, Obesity & Metabolism. 2021 Jun 1
• 3 citations
  Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency.
  Annaswamy Raji, Zhi Jin Xu, Raymond L. H. Lam, Edward A. O'Neill, Keith D. Kaufman, Samuel S. Engel> ;Diabetes Therapy. 2020 Aug 27
• 3 citations
  Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients ...
  Juan P. Frias, Zachary Zimmer, Raymond L. H. Lam, Guillermo Amorin, Catherine Ntabadde, Carol Iredale, Edward A. O'Neill, Samuel S. Engel, Keith D. Kaufman, Hideo Maki...> ;Diabetes, Obesity & Metabolism. 2019 May 1
• 16 citations
  Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiati...
  Ronan Roussel, S Durán-Garcia, Yilong Zhang, Suneri Shah, Carolyn Darmiento, R. Ravi Shankar, Gregory T. Golm, Raymond L. H. Lam, Edward A. O'Neill, Ira Gantz, Keith D...> ;Diabetes, Obesity & Metabolism. 2019 Apr 1
• 28 citations
  A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficienc...
  Russell S. Scott, Jerry D. Morgan, Zachary Zimmer, Raymond L. H. Lam, Edward A. O'Neill, Keith D. Kaufman, Samuel S. Engel, Annaswamy Raji> ;Diabetes, Obesity & Metabolism. 2018 Dec 1
• 4 citations
  Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
  Shelby D. Reed, Yanhong Li, Jose Leal, Larry Radican, Amanda I Adler, Joakim Alfredsson, John B. Buse, Jennifer B. Green, Keith D. Kaufman, Axel Riefflin, Frans Van de...> ;Diabetes, Obesity & Metabolism. 2018 Jul 1
• 53 citations
  Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.
  Abhinav Sharma, Jennifer B. Green, Allison Dunning, Yuliya Lokhnygina, Sana M. Al-Khatib, Renato D. Lopes, John B. Buse, John M. Lachin, Frans Van de Werf, Paul W. Arm...> ;Diabetes Care. 2017 Dec 1
• 8 citations
  A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mel...
  Seung-Hwan Lee, Ira Gantz, Elizabeth Round, Melanie Latham, Edward A. O'Neill, Paulette Ceesay, Shailaja Suryawanshi, Keith D. Kaufman, Samuel S. Engel, Eseng Lai> ;BMC Endocrine Disorders. 2017 Nov 6
• 24 citations
  A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patient...
  Ira Gantz, Taro Okamoto, Yuka Ito, Kotoba Okuyama, Edward A. O'Neill, Keith D. Kaufman, Samuel S. Engel, Eseng Lai> ;Diabetes, Obesity & Metabolism. 2017 Nov 1
• 10 citations
  A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with ty...
  Philip Home, R. Ravi Shankar, Ira Gantz, Carol Iredale, Edward A. O'Neill, Lokesh Jain, Annpey Pong, Shailaja Suryawanshi, Samuel S. Engel, Keith D. Kaufman, Eseng Lai> ;Diabetes Research and Clinical Practice. 2017 Oct 1
• 5 citations
  Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds
  Ira Gantz, L.K. Sokolova, Lokesh Jain, Carol Iredale, Edward A. O'Neill, Ziwen Wei, Raymond L. H. Lam, Shailaja Suryawanshi, Keith D. Kaufman, Samuel S. Engel, Eseng Lai> ;Clinical Therapeutics. 2017 Oct 1
• 77 citations
  A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
  Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Catherine Ntabadde, Sukrut Shah, Edward A. O'Neill, Samuel S. Engel, Keith D. Kaufman, Eseng Lai> ;Cardiovascular Diabetology. 2017 Sep 11
• 11 citations
  A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with ty...
  Yehuda Handelsman, Brett Lauring, Ira Gantz, Carol Iredale, Edward A. O'Neill, Ziwen Wei, Shailaja Suryawanshi, Keith D. Kaufman, Samuel S. Engel, Eseng Lai> ;Current Medical Research and Opinion. 2017 Jun 28
• 9 citations
  A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadeq...
  R. Ravi Shankar, Silvio E. Inzucchi, Victoria Scarabello, Ira Gantz, Keith D. Kaufman, Eseng Lai, Paulette Ceesay, Shailaja Suryawanshi, Samuel S. Engel> ;Current Medical Research and Opinion. 2017 Jun 23
• 41 citations
  Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
  M. Angelyn Bethel, Samuel S. Engel, Jennifer B. Green, Zhen Huang, Robert G. Josse, Keith D. Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Darren ...> ;Diabetes Care. 2017 Apr 1
• 17 citations
  Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily D...
  Ronald Goldenberg, Ira Gantz, Paula J. Andryuk, Edward A. O'Neill, Keith D. Kaufman, Eseng Lai, Yin Na Wang, Shailaja Suryawanshi, Samuel S. Engel> ;Diabetes, Obesity & Metabolism. 2017 Mar 1
• 10 citations
  A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone
  Weiqing Wang, Guang Ning, Jianhua Ma, Xiaomin Liu, Shaoxiong Zheng, Fan Wu, Lei Xu, Edward A. O'Neill, Kenji P Fujita, Samuel S. Engel, Keith D. Kaufman, R. Ravi Shankar> ;Current Medical Research and Opinion. 2017 Jan 25
• 42 citations
  Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
  Robert G. Josse, Sumit R. Majumdar, Yinggan Zheng, Amanda I Adler, M. Angelyn Bethel, John B. Buse, Jennifer B. Green, Keith D. Kaufman, Helena W. Rodbard, Tsvetalina ...> ;Diabetes, Obesity & Metabolism. 2017 Jan 1
• 123 citations
  Androgens and alopecia.
  Keith D. Kaufman> ;Molecular and Cellular Endocrinology. 2002 Dec 30
• 25 citations
  A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes m...
  Robert G. Moses, Elizabeth Round, Yue Shentu, Gregory T. Golm, Edward A. O'Neill, Ira Gantz, Samuel S. Engel, Keith D. Kaufman, Barry J. Goldstein> ;Journal of Diabetes. 2016 Sep 1
• Join now to see all

Journal Articles

• A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficienc...  
  Keith Kaufman, MD, Diabetes, Obesity and Metabolism